March eUpdate from FDA Office of Women's Health

"FDA Office of Women's Health" <fda@xxxxxxxxxxxxxxxxxxxxxxx> · Thu, 12 Mar 2015 13:56:15 -0500

Title:     March eUpdate from FDA Office of Women's Health

            March 2015
www.fda.gov/womens

            Message from the Director

It’s
Women’s History Month. We are once again taking stock of our past while also focusing on the important women’s health issues of
today. I encourage you to learn more about the historic contributions of women
scientists at FDA and to view the timeline
of FDA contributions to women’s health in the last 20 years. I also
encourage you to view the new women’s
health research and educational
resources highlighted in this update. 

           FDA Women's Health Highlights

           2015 OWH Research Grants

OWH has
selected 16 research projects for FY 2015 funding.  Projects were selected that (1) leverage
current or past peer-reviewed women’s health research projects or (2) support
of the implementation of the FDASIA Section 907 Action Plan. The outcomes of
the research will help FDA develop innovative approaches to identify and
evaluate sex differences and assess the safety and efficacy of medical products
used primarily by women. 

View
the 2015 list of OWH-funded research projects.
Women and HIV Resources

Use these FDA resources to help the women in your
community learn the facts about HIV testing, prevention, and treatment.

Download and share our
fact sheet. 
Use our
guide  to help women living with HIV talk to their doctor about their
medicines.
Learn about pregnancy
registry studies that track women with HIV who take HIV medicines during
pregnancy.

Read the latest HIV news and
alerts from FDA.

           Tips for a Safer Spring Break

FDA has
digital tools and free materials to prepare college women for Spring Break.
Help spread the word about these resources and encourage students to stay safe
while they are on vacation. 

Link to our College
     Women’s Health site for tips and resources.
Share 5
     Tips for a Safer Spring Break.
Repin our Spring Break pin
     on Pinterest.
Retweet Spring Break tips from @FDAWomen.

                              Extras

           Drug Safety Communication for Stop Smoking Drug

FDA is
warning that the prescription smoking cessation medicine Chantix (varenicline)
can change the way people react to alcohol. In addition, rare accounts of
seizures in patients treated with Chantix have been reported. FDA has approved
changes to the Chantix label to warn about these risks. Until patients know how
Chantix affects their ability to tolerate alcohol, they should decrease the
amount of alcohol they drink. Patients who have a seizure while taking Chantix
should stop the medicine and seek medical attention immediately.

Read
the Drug Safety
Communication
New Book Chapter on Sex Differences in Drug Pharmacokinetics

Learn
more about the impact of sex differences on drug safety from a chapter from FDA
in the new book Medicines
in Women.
Fadiran, E.O., Zhang, L.
     (2015) Effects of Sex Differences in the Pharmacokinetics of Drugs and
     Their Impact on the Safety of Medicines in Women. M. Harrison-Woolrych
     (e.d) Medicines in Women.  (pp. 41-68)

            FDA Meetings

Public Conference:
The Importance of Getting It Right – How to Measure and Interpret Drug-Induced
Liver Injury Information and Make Correct Diagnoses

March 18-19,
2015
College
Park Marriott Hotel and Conference Center, Hyattsville, MD

Joint
Meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and
Risk Management Advisory Committee

March
19, 2015

Holiday
Inn Gaithersburg, Gaithersburg, MD

Public Meeting on
Breast Cancer Patient-Focused Drug Development 

April
2, 2015 

FDA
White Oak Campus, Silver Spring, MD

      Please share this update with your network, members, constituents, and community

FDA Office of Women's Health
10903 New Hampshire Avenue
WO32 - Room 2333
Silver Spring, MD 20993*0002
301-796-9440

Subscriber Services: 
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420